Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The Company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectious human diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma.
Traversa's siRNA delivery technology is specifically designed to avoid the physical size and bioavailability problems inherent in the Liposome/cationic-lipid approach. The technology is non-cytotoxic, delivers to the entire cell population and all cell-types tested, and is dramatically smaller than a liposome. The Company expects the technology to provide improved pharmacokinetics, distribution and bioavailability over other methods. The technology supports delivery to primary and tumor cells, T cells, B cells, Macrophage, neuronal cells and human stem cells, where other approaches have failed.
Learn About Traversa's Technology
- March 25, 2010 Traversa Therapeutics and sanofi-aventis enter into a research agreement for the development of Traversa's RNAi delivery technology
- January 6, 2010 Traversa Appoints Curt W. Bradshaw, Ph.D. as VP of Research & Development
- April 2, 2009 Traversa Therapeutics Completes Series B Financing. Company continues to advance toward the clinic with novel RNA interference technologies.
- March 24, 2009 Traversa Therapeutics announces appointment of William G. Kaelin, Jr., M.D. and Yitzhak Tor, Ph.D. to the company's scientific advisory board
